SUPN Valuation

Supernus Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

46.020

-1.245(-2.634%)1D

SUPN Relative Valuation

SUPN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SUPN is overvalued; if below, it's undervalued.

Historical Valuation

Supernus Pharmaceuticals Inc (SUPN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.52 is considered Undervalued compared with the five-year average of 21.55. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 60.40 to 86.90 according to relative valuation methord. Compared to the current price of 46.02 USD , Supernus Pharmaceuticals Inc is Undervalued By 23.81%.

Relative Value

Fair Zone

60.40-86.90

Current Price：46.02

23.81%

Undervalued

16.52

Trailing

Forward

12.60

EV/EBITDA

Supernus Pharmaceuticals Inc. (SUPN) has a current EV/EBITDA of 12.60. The 5-year average EV/EBITDA is 13.50. The thresholds are as follows: Strongly Undervalued below 1.59, Undervalued between 1.59 and 7.54, Fairly Valued between 19.45 and 7.54, Overvalued between 19.45 and 25.40, and Strongly Overvalued above 25.40. The current Forward EV/EBITDA of 12.60 falls within the Historic Trend Line -Fairly Valued range.

13.49

EV/EBIT

Supernus Pharmaceuticals Inc. (SUPN) has a current EV/EBIT of 13.49. The 5-year average EV/EBIT is 4.39. The thresholds are as follows: Strongly Undervalued below -223.67, Undervalued between -223.67 and -109.64, Fairly Valued between 118.42 and -109.64, Overvalued between 118.42 and 232.45, and Strongly Overvalued above 232.45. The current Forward EV/EBIT of 13.49 falls within the Historic Trend Line -Fairly Valued range.

46.02

Supernus Pharmaceuticals Inc. (SUPN) has a current PS of 46.02. The 5-year average PS is 3.13. The thresholds are as follows: Strongly Undervalued below -5.35, Undervalued between -5.35 and -1.11, Fairly Valued between 7.36 and -1.11, Overvalued between 7.36 and 11.60, and Strongly Overvalued above 11.60. The current Forward PS of 46.02 falls within the Strongly Overvalued range.

13.33

P/OCF

Supernus Pharmaceuticals Inc. (SUPN) has a current P/OCF of 13.33. The 5-year average P/OCF is 9.61. The thresholds are as follows: Strongly Undervalued below 3.68, Undervalued between 3.68 and 6.64, Fairly Valued between 12.57 and 6.64, Overvalued between 12.57 and 15.54, and Strongly Overvalued above 15.54. The current Forward P/OCF of 13.33 falls within the Overvalued range.

19.08

P/FCF

Supernus Pharmaceuticals Inc. (SUPN) has a current P/FCF of 19.08. The 5-year average P/FCF is 19.93. The thresholds are as follows: Strongly Undervalued below 9.21, Undervalued between 9.21 and 14.57, Fairly Valued between 25.29 and 14.57, Overvalued between 25.29 and 30.65, and Strongly Overvalued above 30.65. The current Forward P/FCF of 19.08 falls within the Historic Trend Line -Fairly Valued range.

Supernus Pharmaceuticals Inc (SUPN) has a current Price-to-Book (P/B) ratio of 2.50. Compared to its 3-year average P/B ratio of 1.95 , the current P/B ratio is approximately 28.62% higher. Relative to its 5-year average P/B ratio of 1.95, the current P/B ratio is about 28.15% higher. Supernus Pharmaceuticals Inc (SUPN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 7.24%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.61% , the current FCF yield is about -100.00% lower.

2.50

P/B

Median3y

1.95

Median5y

1.95

0.00

FCF Yield

Median3y

7.24

Median5y

7.61

Competitors Valuation Multiple

The average P/S ratio for SUPN's competitors is 44.50, providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN) exhibits a P/S ratio of 46.02, which is 3.42% above the industry average. Given its robust revenue growth of 7.41%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SUPN.O

Supernus Pharmaceuticals Inc

Arcutis Biotherapeutics Inc

Travere Therapeutics Inc

Prestige Consumer Healthcare Inc

Xenon Pharmaceuticals Inc

38.25

2.96B

TARS.O

Tarsus Pharmaceuticals Inc

66.20

146.68%

2.90B

Performance Decomposition

Market capitalization of SUPN increased by 25.84% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -41.13 to -134.73.

The secondary factor is the Revenue Growth, contributed 7.41%to the performance.

Overall, the performance of SUPN in the past 1 year is driven by P/E Change. Which is more unsustainable.

7.41%

175.69M → 188.71M

Revenue Growth

-209.13%

21.91 → -23.91

Margin Expansion

227.56%

-41.13 → -134.73

P/E Change

25.84%